ELAVL1 and cancer: The HuR protein has been described as involved in tumor aggressiveness [45], cancer ethiology [19] and proposed as a potential drug target [46,47] in cancer but, when we coadministered rottlerin and doxo, we observed an antagonistic effect of the two drugs on cell viability.